Skip to main content
Clinical Trials/NCT03754257
NCT03754257
Completed
Not Applicable

Effects of Electrical Stimulation for Preventing Loss of Muscle Mass in Patients With SIRS, Sepsis and Septic Shock - Randomized, Controlled and Double-blind Clinical Trial

Hospital Sirio-Libanes1 site in 1 country36 target enrollmentOctober 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Hospital Sirio-Libanes
Enrollment
36
Locations
1
Primary Endpoint
Muscle mass
Status
Completed
Last Updated
last year

Overview

Brief Summary

Background: Electrical stimulation has been used in critical patients as an adjunct strategy of early rehabilitation. In septic or septic shock patients there are reports of only two studies in the literature, with conflicting results.

Objective: To evaluate the effects of electrical stimulation in the prevention of muscle mass loss in patients admitted to the ICU with systemic inflammatory response syndrome (SIRS), sepsis or septic shock.

Methods: This is a randomized, controlled, double-blind clinical trial. Thirty-six patients with a diagnosis of SIRS, sepsis or septic shock (including patients with sepsis due to the new coronavirus - COVID-19) will be randomly assigned to experimental group and sham group. They will be evaluated in relation to muscle mass, peripheral muscle strength and functional status. They will also be submitted to the collection of inflammatory, metabolic, damage and muscular trophism markers.

Expected results: Electrical stimulation is expected to be able to prevent loss of muscle mass in patients admitted to the ICU with SIRS, sepsis or septic shock. In addition, it is expected to be able to preserve strength in this population without increasing the pro-inflammatory or metabolic response.

Detailed Description

This is a randomized, controlled, double-blind clinical trial. Thirty-six patients with a diagnosis of SIRS, sepsis or septic shock (including patients with sepsis due to the new coronavirus - COVID-19) will be randomly assigned to experimental group and sham group.They will be evaluated in relation to muscle mass, peripheral muscle strength and functional status. They will also be submitted to the collection of inflammatory, metabolic, damage and muscular trophism markers.

Registry
clinicaltrials.gov
Start Date
October 1, 2018
End Date
October 21, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hospital Sirio-Libanes
Responsible Party
Principal Investigator
Principal Investigator

Wellington Yamaguti

Wellington Pereira dos Santos Yamaguti

Hospital Sirio-Libanes

Eligibility Criteria

Inclusion Criteria

  • patients admitted to the ICU with a diagnosis of SIRS, sepsis or septic shock,
  • aged ≥ 18 years,
  • body mass index (BMI) ≤ 35 kg / m2,
  • without diabetic polyneuropathy,
  • without cardiac pacemaker,
  • without diagnosis of neuromuscular diseases,
  • absence of skin lesions.

Exclusion Criteria

  • heart attack,

Outcomes

Primary Outcomes

Muscle mass

Time Frame: 8 days

Thickness

Secondary Outcomes

  • Peripheral muscle strength(8 days)
  • Functional status(8 days)
  • Inflammatory(5 days)
  • Metabolic, damage and muscular trophism markers(5 days)

Study Sites (1)

Loading locations...

Similar Trials